Is azithromycin (Zithromax) prophylaxis a rational approach on the side of bronchoscopic biopsy?

Oguz KARABAY
Abant Izzet Baysal Universty, Izzet Baysal Skill of Drug, Department of Infectious Diseases and Clinical Microbiology, 14280 Bolu, Turkey

I look over the article by Kanazawa with serious interest. Kanazawa concluded that a 3-day course of azithromycin management was pretentiously tolerated and powerful in preventing infection post bronchoscopy.
I take two pipeline objections against this study. Earliest, we remember that prophylactic antibiotics ampicillin or cefazolin or clindamycin should be given 30 min ahead of bronchoscopy purely to patients with asplenia, prosthetic valve or depiction of endocarditis. The case, is azithromycin prophylaxis (or treatment) really required for the benefit of preventing infection enter bronchoscopy?
Today, it is brim over known that the extravagant use of antibiotics in the outpatient setting has contributed to the better in antimicrobial resistance. Growing grounds suggest that equal of the most vital factors in the evolution of denial is the unneeded antibiotic use. Areas within the community with the highest rebelliousness rates from the highest antimicrobial speak, and increased duration of serene baring to antimicrobials increases the likelihood of colonization with intransigent organisms.
Azithromycin (Zithromax online) is recommended as a first-line drug for the treatment of community acquired pneumonia because it is effective against Streptococcus pneumoniae, Haemophilus influenzae and Mycoplasma pneumoniae. So, passive resistance to azithromycin (Zithromax) is a exceptionally high-level issue. I suppose that the conclusion of the article may trick clinician to manoeuvre azithromycin unnecessarily, which will most all things considered terminate in the surfacing of azithromycin (Zithromax) stubbornness, and unnecessary get and drug side-effects such as diarrhoea. Reducing rates of antibiotic usage an eye to hackneyed standard operating procedure such as fibre-optic bronchoscopy, has signal implications not merely in the interest both nearest and future antimicrobial recalcitrance problems, but for health-care costs as well.
Lastly, Kanazawa's article reported two patients into the open of 310 subjects having lung abscess after fibril optic bronchoscopy in the no treatment group. I think that this price is higher than expected. I could unearth sole bromide circulate all over lung abscess complicating transbronchial biopsy in the English language literature. Are there possible important predisposing factors (such as immunosuppressive treatment) in the no- treatment set apart correct to this intoxicated at all events of lung abscess? If so, is unaggressive selection of the study appropriate and is statically rating of this swot even now valid?